Key decisions from the 41st Global Fund Board meeting

Ian MatthewsArticle

GBCHealth provided valuable support to the Private Sector Delegation (PSD) during the Global Fund’s recent 41st Board meeting, held in Geneva, Switzerland on 15 and 16 May.

The Board of the Global Fund approved a new allocation methodology and catalytic investment priorities for the 2020-2022 funding cycle. The Board also had an opportunity to touch upon key resource mobilization issues, particularly in preparation for the upcoming replenishment, and other matters associated with the need to further refine strategic reporting and risk management strategies.

An issue of particular interest to the private sector, the Board approved a revision to the Policy for Restricted Financial Contributions. This policy change aims to unlock new sources of funding, allowing the private sector to (1) provide funding that exceeds the value of Global Fund grants in a country and (2) contribute toward catalytic investments.

This meeting also served to introduce the new Board Chair and Vice-Chair, Donald Kaberuka and Lady Roslyn Morauta, whose terms begun as the 41st session of the Board was adjourned.

Other approved decisions included the release of financial statements and re-appointment of the External Auditor.

Private Sector Delegation (PSD) updates

  • Paul Schaper of Merck, Sharp & Dohme, incoming PSD Alternate Board member, succeeded Brian Brink as Chair of the Donor Group of the Global Fund Board.
  • As of the end of the 41st Board meeting, Sherwin Charles of Goodbye Malaria started his first term as PSD Board member, while Paul Schaper transitioned into his second term as PSD Alternate Board member.
Ian MatthewsKey decisions from the 41st Global Fund Board meeting